The risk of progressive multifocal leukoencephalopathy (PML) associated with prolonged natalizumab use in JCV-seropositive patients might motivate clinicians to switch patients with multiple sclerosis (MS) to fingolimod.(1,2) Many patients with MS taking natalizumab have failed first-line therapies such as interferon-β or glatiramer acetate, and are unlikely to respond to the same therapies after natalizumab.
No takes yet. Share an insight, caveat, or question.
Centonze et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: